Meeting
2022 ASCO Annual Meeting
Phase I study of 131I-MIBG with dinutuximab for patients with relapsed or refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium.
Authors
Thomas Cash
Aflac Cancer & Blood Disorders Center, Children’s Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA
Thomas Cash , Araz Marachelian , Steven G. DuBois , Yueh-Yun Chi , Susan G. Groshen , Anasheh Shamirian , Alina C Stout , Margaret E Macy , Navin R. Pinto , Ami Vijay Desai , Paul M. Sondel , Shahab Asgharzadeh , Brian D. Weiss , Yael P. Mosse , Katherine K. Matthay , Julie R. Park , Kelly C. Goldsmith
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT03332667
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 10038)
DOI
10.1200/JCO.2022.40.16_suppl.10038
Abstract #
10038
Poster Bd #
253
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1b study of crizotinib in combination with temsirolimus in pediatric ALK- or MET-aberrated relapsed or refractory neuroblastoma (ITCC-053): Results of the phase 1 part.
First Author: Kim Schellekens
Poster
2022 ASCO Annual Meeting
Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: Results of "HITS" phase II study.
First Author: Shakeel Modak
Poster
2014 ASCO Annual Meeting
Phase II study of 131I-MIBG with vincristine and 5 days of irinotecan for patients with relapsed or refractory neuroblastoma.
First Author: Steven G. DuBois
Poster
2023 ASCO Annual Meeting
Single-agent activity of the anti-GD2 antibody dinutuximab beta given as a long-term infusion in relapsed and refractory neuroblastoma (APN311-304).
First Author: Holger N. Lode